High-impact research history spanning basic science research through to clinical research Prof Chong is a clinician scientist, a haematologist and an educator with a national and international reputation, and is known particularly for his expertise in the field of thrombosis and haemostasis. He has an established basic science research profile with expertise in molecular and cell biology and immunopathology. He also have an established clinical research profile and has a Clinical Research Unit (CTU) which currently employs 9 research nurses and data managers and conducts Phase I-IV trials, with expertise well recognised by industry (locally and internationally) and research institutes alike (the CTU is upheld as an exemplary centre and is regularly used in pilot initiatives driven by the NSW Cancer Institute). This infrastructure is invaluable in seeing the research translated from bench to bedside. The research that he has driven to date has changed paradigms e.g. his work has changed concepts regarding the regulation of platelet production by thrombopoietin (TPO) by showing the existence of a feedback mechanism of TPO regulation in the bone marrow rather than only by the liver and kidneys at a constant rate regardless of the blood platelet levels. His work has resulted in major discoveries e.g. an immune mechanism of heparin-induced thrombocytopenia (HIT) and identification of GPIX as the major autoantigen in drug-induced thrombocytopenia. Similarly the advances Prof Chong has made, have a substantial impact on clinician options and patient outcomes e.g. his work has led to an effective treatment for HIT where none existed at that time and has resulted in significant numbers of lives being saved. In addition, his work has led to better treatment options for venous thromboembolism (VTE) and immune thrombocytopenia (ITP). Driving research with clinical applications by working in clinical practice Prof Chong is able to see areas of need to clinicians and drive research to meet those needs. His research has seen major advances in patient care in immune ITP, HIT as well as VTE prevention and treatment.